Recombinant IFN-γ treatment of a patient with hyperimmunoglobulin E syndrome triggered autoimmune thrombocytopenia
Recombinant IFN-γ treatment of a patient with hyperimmunoglobulin E syndrome triggered autoimmune thrombocytopenia
复制标题
DOI：
10.1089/jir.1998.18.561
复制
发表时间：
1998-08-01
影响因子：
2.3
通讯作者：
Yokota, S
中科院分区：
文献类型：
--
作者：
Aihara, Y;Mori, M;Yokota, S
我们报告一位患有高免疫球蛋白E综合征（HIES）的儿童患者，接受重组干扰素-γ（rIFN-γ）治疗2年1/4，出现自身免疫性血小板减少症，血清抗血小板抗体和抗核抗体（ANA）阳性。然后，她接受静脉注射甲基强的松龙脉冲治疗，随后口服免疫抑制药物。通过这种治疗，她的血小板计数增加，并保持在正常范围内一年多。我们回顾性地检查了她在-40 ℃下储存的血清中的ANA，发现用rIFN-γ治疗后ANA水平从1：40增加到1：640。因此，我们认为，在这种情况下，rIFN-γ治疗可能在触发自身免疫性血小板减少症中发挥了至关重要的作用。此外，该病例表明，对遗传易感患者给予rIFN-γ时必须谨慎。
We report a pediatric patient with hyperimmunoglobulin E syndrome (HIES) treated with recombinant IFN-gamma (rIFN-gamma) for 2 1/4 years who developed autoimmune thrombocytopenia and was positive for serum antiplatelet antibody and antinuclear antibody (ANA). She was then treated with i.v. methylprednisolone pulse therapy followed by oral immunosuppressive drugs. With this therapy, her platelet count increased and was maintained within the normal range for more than a year. We retrospectively examined her sera stored at -40 degrees C for ANA and found that the ANA level was increased from 1:40 to 1:640 with the rIFN-gamma therapy. Therefore, we believe that, in this case, rIFN-gamma treatment may have played a crucial role in triggering autoimmune thrombocytopenia. Furthermore, this case demonstrates that caution must be observed in administering rIFN-gamma to genetically predisposed patients.